<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080465</url>
  </required_header>
  <id_info>
    <org_study_id>UAB00240818-1</org_study_id>
    <nct_id>NCT05080465</nct_id>
  </id_info>
  <brief_title>Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis</brief_title>
  <official_title>Long Term Follow up Autologous Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ukraine Association of Biobank</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ukraine Association of Biobank</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess safety and preliminary clinical activity of treatments of liver&#xD;
      cirrhosis in patients with caused by Hepatitis C and Hepatitis B or Nonalcoholic&#xD;
      Steatohepatitis of Mesenchymal stem cell.&#xD;
&#xD;
      Patients who will be enrolled in the study will be under supervision and monitoring to ensure&#xD;
      clinical significance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver cirrhosis refers to extreme scarring of the liver, resulting in suboptimal function of&#xD;
      the liver. It can result from a variety of causes, ranging from hepatitis B and C infection,&#xD;
      excessive alcohol consumption, autoimmune causes, fatty liver and others. Irrespective of the&#xD;
      cause, once the liver becomes cirrhotic, it is a downhill course.&#xD;
&#xD;
      Liver cirrhosis is irreversible and most patients will progressively worsen over time. Once&#xD;
      liver cirrhosis has reached the stage of decompensation, that is, development of jaundice,&#xD;
      ascites, variceal bleeding, hepatic encephalopathy and coagulopathy the two-year survival&#xD;
      drops to about 50%.&#xD;
&#xD;
      The definitive treatment of decompensated cirrhosis is liver transplantation. While a liver&#xD;
      transplantation is potentially curative, the high costs, lack of a donor, treatment-related&#xD;
      mortality and the immunosuppression complications make this option possible only for a&#xD;
      limited number of patients. The vast majority do not have an effective option at all, thus&#xD;
      the need to develop alternative therapies. Various types of Stem Cells had been investigated&#xD;
      as a regenerative therapy for liver cirrhosis. These stem cells include bone marrow&#xD;
      mesenchymal stem cells (MSC). Some early studies have shown encouraging results in patients&#xD;
      who had autologous bone marrow stem cell transplantation. There was improved liver function&#xD;
      in these patients with cirrhotic livers.&#xD;
&#xD;
      The sponsor is proposing a study to look into the role of MSC therapy for patients with liver&#xD;
      cirrhosis in Ukraine. This will be a Phase I study with the main emphasis on the safety and&#xD;
      efficiency profile first. The trial will be conducted in compliance with the protocol, GCP&#xD;
      and local regulatory requirement(s).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2, 2018</start_date>
  <completion_date type="Anticipated">February 2, 2022</completion_date>
  <primary_completion_date type="Actual">October 7, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>As the primary objective of the study is to assess safety of MSC infusion, a single arm non-blinded study design has been adopted.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MR Elastography</measure>
    <time_frame>Change from Baseline (Day 0) until 40 weeks</time_frame>
    <description>The detect liver stiffness of significant or severe fibrosis (≥stage F2)\(≥stage F3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of serum alanine aminotransferase (ALT)</measure>
    <time_frame>Change from Baseline (Day 0) until 40 weeks</time_frame>
    <description>level of serum alanine aminotransferase less 40 (IU/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Examination</measure>
    <time_frame>Change from Baseline (Day 0) until 40 weeks</time_frame>
    <description>To observe for the following:&#xD;
absence of grade IV anaphylactic reactions (in reference to CTCAE 4.03)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The level of glomerular filtration rate (GFR)</measure>
    <time_frame>Change from Baseline (Day 0) until 40 weeks</time_frame>
    <description>The level of glomerular filtration range from 90 to 120 mL/min/1.73 m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of serum albumin (ALB)</measure>
    <time_frame>Up to 6 months, post-infusion</time_frame>
    <description>The level of serum albumin to 5.4 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of serum total bilirubin (TB)</measure>
    <time_frame>Up to 6 months, post-infusion</time_frame>
    <description>The level of serum total bilirubin 1.8 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous BM MSC</intervention_name>
    <description>A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Provision of written informed consent for this study by subject or as applicable legal&#xD;
        guardians Able to comply with study requirements Еру rates with RVR defined as serum HCV&#xD;
        RNA undetectable after 12 month after antiviral therapy.&#xD;
&#xD;
        Subject must have documented compensated cirrhosis and no current or past clinical evidence&#xD;
        of decompensated liver disease Subject must have documented history Screening laboratory&#xD;
        result indicating hepatitis C virus (HCV) Genotype 1, 2, 4, 5 or 6 (GT1,2,4,5,6) infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Positive test result at screening for Hepatitis B surface antigen or anti-human&#xD;
        immunodeficiency virus (anti-HIV) antibody HCV genotype performed during screening&#xD;
        indicating co-infection with more than 1 HCV genotype.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Bio-Stem Cell Rehabilitation</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Pathologic Processes</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>MSC Therapy</keyword>
  <keyword>Mesenchymal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

